Jeffrey F. DiBerto

Jeffrey F. DiBerto

Auto-generated profile, based on publicly available information

Jeffrey F. DiBerto

Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Nature
Verified
Journal Article
Closed access
PDF file
AKAnat Levit Kaplan
Anat Levit Kaplan
DCDanielle N. Confair
Danielle N. Confair
KKKuglae Kim
Kuglae Kim
XBXimena Barros-Álvarez
Ximena Barros-Álvarez
RRRamona M. Rodriguiz
Ramona M. Rodriguiz
JEJonathan A. Ellman
Jonathan A. Ellman

21 June 2024 in Science
Verified
Journal Article
Closed access
JLJiankun Lyu
Jiankun Lyu
NKNicholas Kapolka
Nicholas Kapolka
RGRyan Gumpper
Ryan Gumpper
AAAssaf Alon
Assaf Alon
LWLiang Wang
Liang Wang
BRBryan L. Roth
Bryan L. Roth
AlphaFold2 (AF2) models have had wide impact but mixed success in retrospective ligand recognition. We prospectively docked large libraries against unrefined AF2 models of the σ 2 and serotonin 2A (5-HT2A) receptors, testing hundreds of new molecules and comparing results with those obtained from docking against the experimental structures. Hit rates were high and similar for the experimental and AF2 structures, as were affinities. Success in docking against the AF2 models was achieved despite differences between orthosteric residue conformations in the AF2 models and the experimental structures. Determination of the cryo–electron microscopy structure for one of the more potent 5-HT2A ligands from the AF2 docking revealed residue accommodations that resembled the AF2 prediction. AF2 models may sample conformations that differ from experimental structures but remain low energy and relevant for ligand discovery, extending the domain of structure-based drug design.

21 November 2022 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
QQQianhui Qu
Qianhui Qu
WHWeijiao Huang
Weijiao Huang
DADeniz Aydin
Deniz Aydin
JPJoseph M. Paggi
Joseph M. Paggi
ASAlpay B. Seven
Alpay B. Seven
GSGeorgios Skiniotis
Georgios Skiniotis

30 November 2022 in Nature
Verified
Journal Article
Closed access
PDF file
AFAbdelfattah Faouzi
Abdelfattah Faouzi
HWHaoqing Wang
Haoqing Wang
SZSaheem A. Zaidi
Saheem A. Zaidi
JDJeffrey F. DiBerto
Jeffrey F. DiBerto
TCTao Che/Washington Che
Tao Che/Washington Che
SMSusruta Majumdar
Susruta Majumdar

19 November 2021 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
SSSamuel T. Slocum
Samuel T. Slocum
JDJeffrey F. DiBerto
Jeffrey F. DiBerto
BRBryan L. Roth
Bryan L. Roth
A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the United States Food and Drug Administration's designation of psilocybin as a “Breakthrough Therapy” for treatment‐resistant depression, a new path has been forged for the conveyance of psychedelics to the clinic. Essential to the further development of such applications, however, is a clearer understanding of how these drugs exert their effects at the molecular level. Here we review the current knowledge regarding the molecular details of psychedelic drug actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic mechanisms. image

14 February 2023 in Science Signaling
Verified
Journal Article
Closed access
NHNatalie Hewitt
Natalie Hewitt
NMNing Ma
Ning Ma
NANadia Arang
Nadia Arang
SMSarah A. Martin
Sarah A. Martin
AJIT PRAKASHAJIT PRAKASH
AJIT PRAKASH
HDHenrik G. Dohlman
Henrik G. Dohlman
Heterotrimeric guanine nucleotide–binding proteins (G proteins) that function as molecular switches for cellular growth and metabolism are activated by GTP and inactivated by GTP hydrolysis. In uveal melanoma, a conserved glutamine residue critical for GTP hydrolysis in the G protein α subunit is often mutated in Gα q or Gα 11 to either leucine or proline. In contrast, other glutamine mutations or mutations in other Gα subtypes are rare. To uncover the mechanism of the genetic selection and the functional role of this glutamine residue, we analyzed all possible substitutions of this residue in multiple Gα isoforms. Through cell-based measurements of activity, we showed that some mutants were further activated and inactivated by G protein–coupled receptors. Through biochemical, molecular dynamics, and nuclear magnetic resonance–based structural studies, we showed that the Gα mutants were functionally distinct and conformationally diverse, despite their shared inability to hydrolyze GTP. Thus, the catalytic glutamine residue contributes to functions beyond GTP hydrolysis, and these functions include subtype-specific, allosteric modulation of receptor-mediated subunit dissociation. We conclude that G proteins do not function as simple on-off switches. Rather, signaling emerges from an ensemble of active states, a subset of which are favored in disease and may be uniquely responsive to receptor-directed ligands.